Characterizing epigenetic changes in cancer

Methods for cancer epigenetics studies provide insight into tumorigenic pathways and cancer progression

Cancer Epigenetics

Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. As altered methylation often activates or silences genes, changes in the epigenome can affect gene expression and the rate of cancer progression.

Next-generation sequencing (NGS) and microarray technologies can detect altered methylation patterns and other epigenetic changes in cancer. Illumina works with cancer epigenetics experts to ensure its NGS and array solutions meet the field's rapidly evolving needs.

cancer epigenetics illustration

Aberrant methylation is a common epigenetic alteration in cancer. NGS enables researchers to identify and compare methylation in cancer vs. normal cells, and gain insight into methylation patterns at a single nucleotide level.

Learn More About Methylation Sequencing
Tracking Tumor Evolution

Dr. Christopher Mason describes how tumor evolution can be tracked by sequencing the transcriptome, epigenome, and epitranscriptome.

View Video

Methylation arrays enable epigenome-wide association studies that can analyze multiple cancer samples in parallel. Arrays quantitatively interrogate methylation sites across the genome, providing researchers with insight into the regulation of cancer-related genes and pathways.

Learn More About Methylation Arrays
Study Reveals Decreased Average Methylation Levels Years Before Breast Cancer Diagnosis

A study of pre-diagnostic blood samples identifies epigenome-wide hypomethylation changes that may predict breast cancer risk.

Read Publication

Featured Cancer Epigenetics Research

 
Glioma sample
NGS and Methylation Arrays for Brain Tumor Studies

Se Hoon Kim, MD, PhD explains how combining NGS panels with methylation microarrays can deliver value in tumor characterization for clinical research.

Read Interview
Mysteries of Metastasis Article
Methylation and Metastasis

Researchers investigate the epigenetics behind cancer development and metastasis using methylation microarrays and NGS.

Read Interview
Tobacco leaves
The Genetic Basis of Oral Cancer

Researchers identify genomic alterations associated with a deadly oral cancer, including somatic and germline variants as well as changes in promoter methylation and transcription.

Read Interview

Altered transcription factor binding is another common epigenetic change linked to cancer. Chromatin immunoprecipitation sequencing (ChIP-Seq) can provide a genome-wide snapshot of DNA-associated protein activity in cancer vs. normal cells.

The method offers hypothesis-free insights into the regulation of gene expression. Deep sequencing enables detection of lower-abundance protein-DNA interactions often observed with transcription factors.

Learn More About ChIP-Seq
Sequencing the Cancer Epigenome

In episode 49 of the Illumina Genomics Podcast, Dr. Susan Clark discusses the role of epigenetics in cancer and human biology.

Listen Now
Surveying the Chromatin Landscape with NGS

A method that maps open chromatin regions helps researchers gain a better understanding of the epigenome and its impact on cancer and autoimmune diseases.

Read Article
Surveying the Chromatin Landscape Article
Infinium MethylationEPIC BeadChip Kit
  • Microarray featuring expert-selected content
  • Coverage of > 850,000 methylation sites per sample at single-nucleotide resolution
  • FFPE compatibility
View Product
iScan Array Scanner
  • High sample throughput
  • Flexibility for multiple applications
  • High data quality
  • Automation compatibility
View System
TruSeq Methyl Capture EPIC Library Prep Kit
  • Targeted methylation sequencing
  • Targets over 3.3 million CpGs. Interrogates biologically important methylome targets.
  • 500 ng human genomic DNA input
View Product
The Power and Promise of Liquid Biopsies
The Power and Promise of Liquid Biopsies

By: Dr. Phil Febbo, Chief Medical Officer at Illumina

Read Article
Identifying lncRNA Biomarkers in Highly Fragmented RNA Samples
Identifying lncRNA Biomarkers in Highly Fragmented RNA Samples

Optimizing NextSeq 500 System and TruSeq RNA Exome Kit RNA sequencing workflows for lncRNA biomarker identification.

Read Interview
Fighting For My Life, I Also Fought For Yours
Fighting For My Life, I Also Fought For Yours

By: Sandra Balladares, Ph.D., Global Marketing Manager at Illumina

Read Article
Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study

Researchers use an Illumina methylation array on tumor and PBLs to identify differences in breast tumor development between African American and non-African American women.

Read Publication
Medulloblastoma subgroups remain stable across primary and metastatic compartments

A methylation fingerprint is used to stratify medulloblastoma subgroups for improved characterization.

Read Publication
Prostate cancer epigenetic biomarkers: next-generation technologies

A review of recent epigenetic discoveries in prostate cancer, highlighting their potential as biomarkers for diagnosis, segmentation, and monitoring.

Read Publication
Image
Field Guide to Methylation Methods

This overview of array- and sequencing-based methylation methods provides a useful resource for cancer epigenetics studies.

Read Guide
Methylation Researcher
DNA Methylation Analysis

Compare methylation sequencing and microarray approaches, and determine the best strategy for your research.

Learn More
Interested in receiving newsletters, case studies, and information on cancer genomics?
Sign Up